Mindbloom is a mental health technology company that offers personalized, evidence-based, virtual psychedelic therapy. The company’s approach targets conditions of emotional distress, such as depression and anxiety. Its website states, “Mindbloom partners with licensed psychiatric clinicians to help their clients get the most out of treatment through technology, content, and hospitality-inspired client experiences.” Mindbloom is venture-backed and headquartered in New York City. Since its founding by CEO Dylan Beynon in 2018, the company has expanded services to 12 states as of summer 2021. 

Currently, Mindbloom only offers ketamine-assisted therapy. Ketamine is technically a dissociative anesthetic but is often compared to classic psychedelic substances due to its consciousness-altering effects, including visual and auditory distortions. Potential clients are first assessed and screened to ensure treatment is suitable for them. Mindbloom’s service package includes a video consultation with a licensed clinician, ketamine doses, 6 guided sessions including preparation and integration sessions, unlimited access to guides, and a plan for post-treatment tailored to the client’s goals. Add-ons include one-on-one integration sessions, group therapy, and themed advanced programs. A clinical team led by medical director Dr. Leonardo Vando and Science Director Dr. Casey Paleos is responsible for ensuring the safety and efficacy of Mindbloom’s treatments approach.

The company has made a notable splash since it emerged, earning high-profile media features in outlets such as Business Insider, Vogue, Newsweek, and Forbes. In the Forbes interview with reporter Javier Hasse, Beynon summarized Mindbloom’s mission, saying “We’re essentially One Medical meets Headspace, but for psychedelic therapy…a person can walk in on their own and get evaluated to do it, rather than going to their doctor and getting a diagnosis, a referral, and doing it in-patient.”

In a March 2020 interview with Deborah Borchardt of Green Market Report, CEO Dylan Beynon stated, “[Ketamine is] our focus today, but we are super excited based on everything I just mentioned plus the research for MDMA assisted therapy, which is in phase three clinical trials, Psilocybin assisted therapy, which is in phase two clinical trials. Both breakthrough therapies designations by the FDA as well as other non-psychedelic medicine treatments that we think can be really powerful to help people with anxiety, depression, and other conditions that we begin helping people with.”

According to the company’s LinkedIn profile, Mindbloom was named among the top 150 digital health startups by CB Insights and one of the 50 Best Places to Work Remotely in 2021 by BuiltIn; CEO Dylan Beynon ranked among the Top 25 Consumer Health Tech Executives of 2020 by the Healthcare Technology Report.